Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 15;12(12):e059669.
doi: 10.1136/bmjopen-2021-059669.

Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data

Collaborators, Affiliations

Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data

Peter Vedsted et al. BMJ Open. .

Abstract

Objectives: A growing body of evidence suggests longer time between symptom onset and start of treatment affects breast cancer prognosis. To explore this association, the International Cancer Benchmarking Partnership Module 4 examined differences in breast cancer diagnostic pathways in 10 jurisdictions across Australia, Canada, Denmark, Norway, Sweden and the UK.

Setting: Primary care in 10 jurisdictions.

Participant: Data were collated from 3471 women aged >40 diagnosed for the first time with breast cancer and surveyed between 2013 and 2015. Data were supplemented by feedback from their primary care physicians (PCPs), cancer treatment specialists and available registry data.

Primary and secondary outcome measures: Patient, primary care, diagnostic and treatment intervals.

Results: Overall, 56% of women reported symptoms to primary care, with 66% first noticing lumps or breast changes. PCPs reported 77% presented with symptoms, of whom 81% were urgently referred with suspicion of cancer (ranging from 62% to 92%; Norway and Victoria). Ranges for median patient, primary care and diagnostic intervals (days) for symptomatic patients were 3-29 (Denmark and Sweden), 0-20 (seven jurisdictions and Ontario) and 8-29 (Denmark and Wales). Ranges for median treatment and total intervals (days) for all patients were 15-39 (Norway, Victoria and Manitoba) and 4-78 days (Sweden, Victoria and Ontario). The 10% longest waits ranged between 101 and 209 days (Sweden and Ontario).

Conclusions: Large international differences in breast cancer diagnostic pathways exist, suggesting some jurisdictions develop more effective strategies to optimise pathways and reduce time intervals. Targeted awareness interventions could also facilitate more timely diagnosis of breast cancer.

Keywords: Adult oncology; Breast tumours; Epidemiology; International health services; PUBLIC HEALTH.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Diagnostic and treatment intervals.
Figure 2
Figure 2
Time intervals for each jurisdiction compared with Wales (reference). Adjusted for differences in comorbidity and age. Differences in interval lengths (in days) are shown for the median, 75th and 90th percentiles compared with the reference used for the regression analyses, Wales. Wales is represented by the axis, with jurisdictions with shorter intervals shown to the left of the axis and jurisdictions with longer intervals shown to the right of the axis for each graph. Solid-fill bars indicate statistically significant differences compared with Wales. Primary care interval is not shown (see table 6).

References

    1. Global burden of disease cancer C, Fitzmaurice C, Dicker D, pain a, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et al: the global burden of cancer 2013. JAMA Oncol 2015;1:505–27. - PMC - PubMed
    1. Allemani C, Matsuda T, Di Carlo V. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1075. 10.1016/S0140-6736(17)33326-3 - DOI - PMC - PubMed
    1. Walters S, Maringe C, Butler J, et al. . Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer 2013;108:1195–208. 10.1038/bjc.2013.6 - DOI - PMC - PubMed
    1. Coleman MP, Forman D, Bryant H, et al. . Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International cancer benchmarking partnership): an analysis of population-based cancer registry data. Lancet 2011;377:127–38. 10.1016/S0140-6736(10)62231-3 - DOI - PMC - PubMed
    1. Niksic M, Rachet B, Duffy SW, et al. . Is cancer survival associated with cancer symptom awareness and barriers to seeking medical help in England? an ecological study. Br J Cancer 2016;115:876–86. 10.1038/bjc.2016.246 - DOI - PMC - PubMed

Publication types